US2013323276A1PendingUtilityA1
Malaria vaccines based on pre-erythrocytic antigens from p. falciparum
Est. expiryDec 6, 2030(~4.4 yrs left)· nominal 20-yr term from priority
A61K 39/002C07K 14/445A61K 2039/57A61K 39/015Y02A50/30
41
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to polypeptides or fragments thereof for use as malaria vaccines. It also relates to nucleic acid molecules coding for the polypeptides of the invention. It further relates to compositions comprising such polypeptides or fragments thereof or the nucleic acid molecules, in particular combinations of such polypeptides or fragments thereof, and the use of such compositions as malaria vaccines.
Claims
exact text as granted — not AI-modified1 . A composition comprising at least two polypeptides, or one or more nucleic acid molecules encoding at least two polypeptides, wherein each of the polypeptides comprises an amino acid sequence selected from
MAL13P1.13
(SEQ ID NO. 1),
PF14_0480
(SEQ ID NO. 2),
MAL13P1.258
(SEQ ID NO. 3),
PF14_0435
(SEQ ID NO. 4),
PF14_0390
(SEQ ID NO. 5),
PF13_0242
(SEQ ID NO. 6),
PF13_0168
(SEQ ID NO. 7),
PF11_0342/0421
(SEQ ID NO. 8),
PFc0515c
(SEQ ID NO. 9),
PFc0135c
(SEQ ID NO. 10),
PF14_0533
(SEQ ID NO. 11),
PF13_0282
(SEQ ID NO. 12),
PF10_0081
(SEQ ID NO. 13),
PFF0420c
(SEQ ID NO. 14),
PF14_0323
(SEQ ID NO. 15),
PF10_0375
(SEQ ID NO. 16),
PF11_0128
(SEQ ID NO. 17),
PF14_0548
(SEQ ID NO. 18),
PF08_0051
(SEQ ID NO. 19),
PF08_0036
(SEQ ID NO. 20),
PF13_0135
(SEQ ID NO. 21),
PF13_0343
(SEQ ID NO. 22),
PFE1260c
(SEQ ID NO. 23),
amino acid sequences that are at least 80% identical to any of the above amino acid sequences, and
fragments of the above amino acid sequences.
2 . (canceled)
3 . The composition of claim 1 , comprising further polypeptide(s), wherein the one or more further polypeptide(s) comprise an amino acid sequence selected from
PF14_0530
(SEQ ID NO. 24),
Mal8P1.134
(SEQ ID NO. 25),
amino acid sequences that have at least 80% sequence identity to any of the amino acid sequences of SEQ ID NOs. 24 and 25, and fragments of the above amino acid sequences.
4 . The composition of claim 1 , wherein the at least two polypeptides are selected from polypeptides comprising an amino acid sequence of SEQ ID NOs. 1 to 25 or fragment(s) thereof or a fragment of one of said amino acid sequences.
5 . The composition of claim 1 , comprising at least three, of the polypeptides or fragments of the polypeptides.
6 . (canceled)
7 . The composition of claim 1 , comprising at least two polypeptides each comprising an amino acid sequence selected from
MAL13P1.13
(SEQ ID NO. 1),
PF14_0480
(SEQ ID NO. 2),
MAL13P1.258
(SEQ ID NO. 3),
PF14_0435
(SEQ ID NO. 4),
PF14_0530
(SEQ ID NO. 24),
PF14_0323
(SEQ ID NO. 15),
amino acid sequences having at least 80% sequence identity to any of the amino acid sequences of SEQ ID NOs. 1 to 4, 15 and 24, and fragments thereof.
8 . The composition of claim 1 , wherein the fragment comprises at least one antigenic determinant or epitope of the amino acid sequence.
9 . The composition of claim 8 , wherein the antigenic determinant or epitope is a CD8+ T cell epitope, a CD4+ T cell epitope.
10 . The composition of claim 8 , wherein the fragment comprises at least one amino acid sequence selected from
(SEQ ID NO. 26)
SLICGLYLL,
(SEQ ID NO. 27)
ILYSLMINSL,
(SEQ ID NO. 28)
LICGLYLLTL,
(SEQ ID NO. 29)
VLLEKINVI,
(SEQ ID NO. 30)
YLSPNFINKI,
(SEQ ID NO. 31)
ILHGGVYRL,
(SEQ ID NO. 32)
ILFLFILSI,
(SEQ ID NO. 33)
LLFINEINKL,
(SEQ ID NO. 34)
SLISLYIYYV,
(SEQ ID NO. 35)
FLLLMLVSI,
(SEQ ID NO. 36)
FLTLMARKL,
(SEQ ID NO. 37)
NLLDPLVVV,
(SEQ ID NO. 38)
LLLEGNFYL,
(SEQ ID NO. 39)
KLIPVNYEL,
and[[/or]]
(SEQ ID NO. 40)
ILIPSLPLI.
11 . The composition of claim 10 , comprising at least one fragment comprising an amino acid sequence selected from
SEQ ID NOs. 26 to 28, SEQ ID NOs. 29 and 30, SEQ ID NOs. 31 to 33, SEQ ID NOs. 34 and 35, SEQ ID NO. 36, and SEQ ID NOs. 37 to 40.
12 . The composition according to claim 1 , wherein the polypeptides or fragments thereof comprise one or more labels, N- and/or C-terminal modifications, drug(s) or other agents.
13 . The composition of claim 1 comprising at least two nucleic acid molecules each encoding at least one polypeptide, or fragment thereof, according to claim 1 .
14 . The composition of claim 13 , comprising at least three of the nucleic acid molecules.
15 . The composition according to claim 1 , further comprising a carrier and/or an adjuvant.
16 . The composition of claim 15 , wherein the carrier is a virus particle or a part thereof, an envelope protein of a viral vector or of a virus particle, or a nanocarrier.
17 . The composition of claim 16 , wherein the virus particle is a Hepatitis 13 virus particle or a part thereof.
18 . The composition of claim 16 , wherein the nanocarrier is a cell-targeted nanocarrier.
19 . The composition of claim 15 , wherein the adjuvant triggers a CD8 T cell response.
20 . A multicomponent malaria vaccine, which comprises a composition of claim 1 .
21 . A method for vaccinating against malaria, wherein said method comprises administering, to a subject in need of such vaccination, a polypeptide, or a nucleic acid molecule encoding said polypeptide, wherein the polypeptide comprises an amino acid sequence selected from SEQ ID NOs. 1 to 23 or an amino acid sequence that is at least 80% identical to any of said amino acid sequences,
or a fragment thereof.
22 . The method, according to claim 21 , wherein the polypeptide comprises an amino acid sequence selected from SEQ ID NOs. 26 to 36.
23 . The method, according to claim 21 , comprising administering to the subject a nucleic acid molecule encoding at least one polypeptide or fragment thereof according to claim 21 .
24 . The method, according to claim 23 , wherein said nucleic acid molecule has a nucleotide sequence selected from SEQ ID NOs. 41 to 63.
25 . The composition of claim 1 , comprising at least five of the polypeptides or fragments of the polypeptides.
26 . The composition of claim 13 , comprising at least five of the nucleic acid molecules.Join the waitlist — get patent alerts
Track US2013323276A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.